Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Gemcitabine 200mg/2ml solution for infusion vials
0801030X0AAAHAH
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 200mg/5.26ml solution for infusion vials
0801030X0AAANAN
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 200mg/5.3ml solution for infusion vials
0801030X0AAAEAE
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 200mg/5ml solution for infusion vials
0801030X0AAAKAK
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 2g powder for solution for infusion vials
0801030X0AAADAD
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 2g/20ml solution for infusion vials
0801030X0AAAJAJ
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 2g/50ml solution for infusion vials
0801030X0AAAMAM
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemcitabine 2g/52.6ml solution for infusion vials
0801030X0AAAGAG
|
Gemcitabine | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemzar 1g powder for solution for infusion vials
0801030X0BBAAAA
|
Gemzar | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Gemzar 200mg powder for solution for infusion vials
0801030X0BBABAB
|
Gemzar | Gemcitabine | Malignant Disease and Immunosuppression | No data available |
|
Generic Rebif initiation pack
0802040M0AAALAL
|
Interferon B | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Generic Teysuno 15mg/4.35mg/11.8mg capsules
0801030ADAAAAAA
|
Tegafur/gimeracil/oteracil | Tegafur/gimeracil/oteracil | Malignant Disease and Immunosuppression | No data available |
|
Generic Teysuno 20mg/5.8mg/15.8mg capsules
0801030ADAAABAB
|
Tegafur/gimeracil/oteracil | Tegafur/gimeracil/oteracil | Malignant Disease and Immunosuppression | No data available |
|
Gestonorone 200mg/2ml solution for injection ampoules
0803020D0AAAAAA
|
Gestonorone hexanoate | Gestonorone hexanoate | Malignant Disease and Immunosuppression | No data available |
|
Gilenya 0.25mg capsules
0802040ADBBABAB
|
Gilenya | Fingolimod | Malignant Disease and Immunosuppression | No data available |
|
Gilenya 0.5mg capsules
0802040ADBBAAAA
|
Gilenya | Fingolimod | Malignant Disease and Immunosuppression | No data available |
|
Gilotrif 20mg tablets
0801050BPBBACAC
|
Gilotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Gilotrif 30mg tablets
0801050BPBBAAAA
|
Gilotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Gilotrif 40mg tablets
0801050BPBBABAB
|
Gilotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Gilteritinib 40mg tablets
0801030AGAAAAAA
|
Gilteritinib | Gilteritinib | Malignant Disease and Immunosuppression | No data available |
|
Giotrif 20mg tablets
0801050BPBCAAAC
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Giotrif 30mg tablets
0801050BPBCABAA
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Giotrif 40mg tablets
0801050BPBCACAB
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Giotrif 50mg tablets
0801050BPBCADAD
|
Giotrif | Afatinib | Malignant Disease and Immunosuppression | No data available |
|
Glatiramer acetate 20mg inj vials
0802040U0AAAAAA
|
Glatiramer acetate | Glatiramer acetate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.